# Evaluation of Pharmacokinetics and Pharmacodynamic Properties of Rapid-Acting Insulin Analogs

> **NCT00652288** · PHASE1 · COMPLETED · sponsor: **Yale University** · enrollment: 36 (actual)

## Conditions studied

- Diabetes Mellitus, Type I

## Interventions

- **DRUG:** Insulin analogs (Lispro and Aspart)
- **DRUG:** Insulin analogs (Aspart and Detemir)
- **DRUG:** Insulin analogs (Aspart and Detemir)
- **DRUG:** Insulin analogs (Lispro and Glargine)
- **DRUG:** Insulin analogs (Lispro and Glargine)

## Key facts

- **NCT ID:** NCT00652288
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-04
- **Primary completion:** 2011-09
- **Final completion:** 2011-09
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2016-09-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00652288

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00652288, "Evaluation of Pharmacokinetics and Pharmacodynamic Properties of Rapid-Acting Insulin Analogs". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT00652288. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*